Widely used:Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹2,555 Cr
Revenue (TTM)
₹1,284 Cr
Net Profit (TTM)
₹1 Cr
ROE
-46.6 %
ROCE
-17.3 %
P/E Ratio
--
P/B Ratio
2.3
Industry P/E
38.43
EV/EBITDA
15.5
Div. Yield
0 %
Debt to Equity
0.1
Book Value
₹228.9
EPS
₹0.1
Face value
10
Shares outstanding
48,153,023
CFO
₹636.25 Cr
EBITDA
₹1,047.28 Cr
Net Profit
₹-238.57 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Solara Active
| -21.9 | 10.3 | 4.3 | 26.1 | 18.0 | -1.2 | -- |
|
BSE Healthcare
| -4.6 | 0.9 | 5.1 | 17.0 | 27.1 | 21.6 | 10.3 |
|
BSE Small Cap
| -4.4 | 1.8 | 13.8 | 1.9 | 29.5 | 33.7 | 17.0 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
Solara Active
| 105.0 | -16.1 | -57.8 | -14.9 | 179.1 | 40.6 |
|
BSE Small Cap
| 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Solara Active
|
530.0 | 2,555.5 | 1,283.8 | 0.5 | 8.3 | 0 | -- | 2.3 |
| 440.7 | 4,051.9 | 2,387.0 | 168.1 | 9.7 | 12.7 | 24.1 | 3.0 | |
| 321.0 | 3,497.8 | 150.8 | 48.8 | 42.1 | 20.7 | 71.7 | 14.1 | |
| 285.1 | 2,629.1 | 1,664.9 | -77.9 | -0.9 | -7.1 | -- | 2.6 | |
| 86.3 | 2,524.9 | 2,079.2 | 101.1 | 6.3 | 6 | 25 | 1.5 | |
| 61.5 | 3,369.9 | 1,811.6 | 118.0 | 8.0 | 10.4 | 28.6 | 2.9 | |
| 689.8 | 3,487.2 | 921.9 | 95.8 | 9.0 | 8 | 35 | 2.8 | |
| 2,381.7 | 3,930.3 | 653.4 | 183.2 | 21.2 | 20.9 | 21.4 | 7.4 | |
| 227.3 | 4,945.9 | 6.7 | -160.8 | -2,578.1 | -106.2 | -- | 45.0 | |
| 586.4 | 4,146.9 | 2,028.9 | 150.6 | 7.5 | 6.2 | 30.2 | 1.7 |
No Review & Analysis are available.
Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America,... South America, and internationally. The company offers APIs for amyotrophic lateral sclerosis, anesthetics, anthelmintic, anti hyperlipidemic, anti-arrhythmic agent, anti-asthmatic, anti-hypertensive, anti-inflammatory, anti-Parkinson, anti-retroviral, antibiotic, anticonvulsant, antidepressant, antifibrinolytics, antifungal, antigout agent, antihelmintic, antihistamine, antihyperlipoproteinemic, antimycotic, antifungal, antineoplastic detoxifying agent, antiprotozoal agent, antipsoriatic, antipsychotic, antitubercular, antiulcer, antiulcerative, anxiolytic, aprepitant, bile acid analogue, calcimimetic agent, cardiovascular agent, chronic alcoholism, treatment of hyperphosphatemia, hemorrheologic agent, hypercholesterolemia, hypophosphatemic agent, immune-suppressant, loop diuretic, NSAIDs, nucleoside inhibitor, OAB treatment, phenylalanine reducer, phosphate binder, reversal of neuro-muscular blocking agent, skeletal muscle relaxant, and topical anti-infectives. It also provides contract research and manufacturing services for APIs, including contract development and manufacturing, analytical services, impurity synthesis, and regulatory support. In addition, the company exports its products. The company was formerly known as SSL Pharma Sciences Limited and changed its name to Solara Active Pharma Sciences Limited in March 2017. Solara Active Pharma Sciences Limited was incorporated in 2017 and is based in Chennai, India. Read more
Incorporated
2017
Chairman
R Ramakrishnan
Managing Director
--
Headquarters
Navi Mumbai, Maharashtra
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Solara Active Pharma Sciences Ltd stood at ₹ 2,232 Cr as on 31-Mar-25
The share price of Solara Active Pharma Sciences Ltd is ₹529.95 (NSE) and ₹530.70 (BSE) as of 20-Jun-2025 IST. Solara Active Pharma Sciences Ltd has given a return of 17.95% in the last 3 years.
Solara Active Pharma Sciences Ltd has a market capitalisation of ₹ 2,555 Cr as on 20-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Solara Active Pharma Sciences Ltd is 2.32 times as on 20-Jun-2025, a 27% discount to its peers’ median range of 3.19 times.
Since, TTM earnings of Solara Active Pharma Sciences Ltd is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Solara Active Pharma Sciences Ltd and enter the required number of quantities and click on buy to purchase the shares of Solara Active Pharma Sciences Ltd.
Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally. The company offers APIs for amyotrophic lateral sclerosis, anesthetics, anthelmintic, anti hyperlipidemic, anti-arrhythmic agent, anti-asthmatic, anti-hypertensive, anti-inflammatory, anti-Parkinson, anti-retroviral, antibiotic, anticonvulsant, antidepressant, antifibrinolytics, antifungal, antigout agent, antihelmintic, antihistamine, antihyperlipoproteinemic, antimycotic, antifungal, antineoplastic detoxifying agent, antiprotozoal agent, antipsoriatic, antipsychotic, antitubercular, antiulcer, antiulcerative, anxiolytic, aprepitant, bile acid analogue, calcimimetic agent, cardiovascular agent, chronic alcoholism, treatment of hyperphosphatemia, hemorrheologic agent, hypercholesterolemia, hypophosphatemic agent, immune-suppressant, loop diuretic, NSAIDs, nucleoside inhibitor, OAB treatment, phenylalanine reducer, phosphate binder, reversal of neuro-muscular blocking agent, skeletal muscle relaxant, and topical anti-infectives. It also provides contract research and manufacturing services for APIs, including contract development and manufacturing, analytical services, impurity synthesis, and regulatory support. In addition, the company exports its products. The company was formerly known as SSL Pharma Sciences Limited and changed its name to Solara Active Pharma Sciences Limited in March 2017. Solara Active Pharma Sciences Limited was incorporated in 2017 and is based in Chennai, India.
The promoters of Solara Active Pharma Sciences Ltd are DEVICAM CAPITAL LLP and PRONOMZ VENTURES LLP. They collectively own 21.1 per cent of the total equity. The chairman of the company is R Ramakrishnan
The promoters of Solara Active Pharma Sciences Ltd have pledged 13.14% of the total equity as on Mar-25.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
5,139
|
|
|
4,280
|
|
|
4,235
|
|
|
3,869
|
|
|
3,637
|
|
|
3,621
|
|
|
3,538
|
|
|
2,608
|
|
|
2,592
|
| Solara Active Pharma Sciences Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
0.05
|
|
Operating margin(%)
|
8.34
|
|
Net Margin(%)
|
0.04
|
|
Dividend yield(%)
|
0
|
Yes, TTM profit after tax of Solara Active Pharma Sciences Ltd was ₹1 Cr.
₹5.70
(
